Cargando…
SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
BACKGROUND: Estimating the cumulative prevalence of SARS-COV-2 will help to understand the epidemic, contagion, and immunity to COVID-19 in vulnerable populations. The objective is to determine the extent of infection in the general population and the cumulative incidence by age group. METHODS: It w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034367/ https://www.ncbi.nlm.nih.gov/pubmed/33868828 http://dx.doi.org/10.7717/peerj.11210 |
_version_ | 1783676533255176192 |
---|---|
author | Díaz-Vélez, Cristian Failoc-Rojas, Virgilio E. Valladares-Garrido, Mario J. Colchado, Juan Carrera-Acosta, Lourdes Becerra, Mileny Moreno Paico, Dafne Ocampo-Salazar, Elgin Thom |
author_facet | Díaz-Vélez, Cristian Failoc-Rojas, Virgilio E. Valladares-Garrido, Mario J. Colchado, Juan Carrera-Acosta, Lourdes Becerra, Mileny Moreno Paico, Dafne Ocampo-Salazar, Elgin Thom |
author_sort | Díaz-Vélez, Cristian |
collection | PubMed |
description | BACKGROUND: Estimating the cumulative prevalence of SARS-COV-2 will help to understand the epidemic, contagion, and immunity to COVID-19 in vulnerable populations. The objective is to determine the extent of infection in the general population and the cumulative incidence by age group. METHODS: It was carried out with a longitudinal analytical study, in the population of the Lambayeque region, located in the north of Peru. The selection was carried out in multistages (districts, area, household, and finally choosing the interviewee within the house). Seroprevalence was estimated as a positive result of the rapid test whether it was positive IgM or positive IgG. An adjustment was made for the sampling weights used. RESULTS: The seroprevalence found in the region was 29.5%. Young people between 21 and 50 years old presented the highest seroprevalence frequencies. A total of 25.4% were asymptomatic. The most frequent complaint was dysgeusia and dysosmia (85.3% and 83.6%). Dysosmia (PR = 1.69), chest pain (PR = 1.49), back pain (PR = 1.45), cough (PR = 1.44), fever (PR = 1.41), general malaise (PR = 1.27) were associated factors with the higher the frequency of seropositivity for SARS-CoV-2. Reporting of complete isolation at home decreased the frequency of positivity (PR = 0.80), however, reporting having ARI contact (PR = 1.60), having contact with a confirmed case (PR = 1.51), and going to market (PR = 1.26) increased the frequency of positivity for SARS-CoV-2. CONCLUSION: These results suggest that Lambayeque is the region with the highest seroprevalence in the world, well above Spain, the United States and similar to a study in India. |
format | Online Article Text |
id | pubmed-8034367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80343672021-04-16 SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 Díaz-Vélez, Cristian Failoc-Rojas, Virgilio E. Valladares-Garrido, Mario J. Colchado, Juan Carrera-Acosta, Lourdes Becerra, Mileny Moreno Paico, Dafne Ocampo-Salazar, Elgin Thom PeerJ Epidemiology BACKGROUND: Estimating the cumulative prevalence of SARS-COV-2 will help to understand the epidemic, contagion, and immunity to COVID-19 in vulnerable populations. The objective is to determine the extent of infection in the general population and the cumulative incidence by age group. METHODS: It was carried out with a longitudinal analytical study, in the population of the Lambayeque region, located in the north of Peru. The selection was carried out in multistages (districts, area, household, and finally choosing the interviewee within the house). Seroprevalence was estimated as a positive result of the rapid test whether it was positive IgM or positive IgG. An adjustment was made for the sampling weights used. RESULTS: The seroprevalence found in the region was 29.5%. Young people between 21 and 50 years old presented the highest seroprevalence frequencies. A total of 25.4% were asymptomatic. The most frequent complaint was dysgeusia and dysosmia (85.3% and 83.6%). Dysosmia (PR = 1.69), chest pain (PR = 1.49), back pain (PR = 1.45), cough (PR = 1.44), fever (PR = 1.41), general malaise (PR = 1.27) were associated factors with the higher the frequency of seropositivity for SARS-CoV-2. Reporting of complete isolation at home decreased the frequency of positivity (PR = 0.80), however, reporting having ARI contact (PR = 1.60), having contact with a confirmed case (PR = 1.51), and going to market (PR = 1.26) increased the frequency of positivity for SARS-CoV-2. CONCLUSION: These results suggest that Lambayeque is the region with the highest seroprevalence in the world, well above Spain, the United States and similar to a study in India. PeerJ Inc. 2021-04-06 /pmc/articles/PMC8034367/ /pubmed/33868828 http://dx.doi.org/10.7717/peerj.11210 Text en © 2021 Díaz-Vélez et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Epidemiology Díaz-Vélez, Cristian Failoc-Rojas, Virgilio E. Valladares-Garrido, Mario J. Colchado, Juan Carrera-Acosta, Lourdes Becerra, Mileny Moreno Paico, Dafne Ocampo-Salazar, Elgin Thom SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 |
title | SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 |
title_full | SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 |
title_fullStr | SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 |
title_full_unstemmed | SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 |
title_short | SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 |
title_sort | sars-cov-2 seroprevalence study in lambayeque, peru. june–july 2020 |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034367/ https://www.ncbi.nlm.nih.gov/pubmed/33868828 http://dx.doi.org/10.7717/peerj.11210 |
work_keys_str_mv | AT diazvelezcristian sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT failocrojasvirgilioe sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT valladaresgarridomarioj sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT colchadojuan sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT carreraacostalourdes sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT becerramileny sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT morenopaicodafne sarscov2seroprevalencestudyinlambayequeperujunejuly2020 AT ocamposalazarelginthom sarscov2seroprevalencestudyinlambayequeperujunejuly2020 |